GenesisCare acquires 21st Century Oncology
December 13, 2019 -- Australian cancer and cardiac care company GenesisCare has acquired U.S.-based radiation therapy and integrated cancer treatment provider 21st Century Oncology.
Senate confirms Hahn as FDA commissioner
December 13, 2019 -- The U.S. Senate has confirmed the Trump administration's nomination of radiation oncologist Dr. Stephen Hahn as commissioner of the U.S. Food and Drug Administration (FDA).
Japanese partnership targets radiotherapeutics
December 13, 2019 -- Osaka University Graduate School of Medicine has signed a collaborative research agreement with Fuzionaire Diagnostics to develop anticancer radiotherapeutic agents.
ASTRO issues rad therapy guidelines for skin cancer
December 11, 2019 -- The American Society for Radiation Oncology (ASTRO) has released new clinical guidelines on using radiation therapy to treat basal and cutaneous squamous cell skin cancers.
Short radiation course for breast cancer shows promise
December 6, 2019 -- A shorter round of higher-dose radiation to part of the breast demonstrates promising results in women with early-stage breast cancer, according to a study published on December 5 in Lancet.
ViewRay inks deal with Elekta, Medtronic
December 4, 2019 -- Image-guided radiation therapy vendor ViewRay has signed a nonbinding memorandum of understanding to collaborate with radiation oncology vendor Elekta and device manufacturer Medtronic on MR-guided radiation therapy.
Cancer patients want more info on treatment downside
November 22, 2019 -- One in three adults wish they had known more about side effects before beginning their cancer treatment, according to the results of a new survey published online November 20 in the Journal of Oncology Practice  Discuss
PTW unveils multipurpose QA rad therapy phantom
November 20, 2019 -- Dosimetry firm PTW has introduced Ruby, a modular, multipurpose phantom designed to provide quality assurance (QA) evaluation of the entire radiotherapy treatment chain.
DOSIsoft gets FDA nod for MU2net software
November 11, 2019 -- Radiation oncology and nuclear medicine software developer DOSIsoft has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its MU2net software for independent secondary dose calculation for patient quality assurance.
Navidea signs immunotherapy deal with IMV
November 7, 2019 -- Radiopharmaceutical developer Navidea Biopharmaceuticals has signed an agreement with biopharmaceutical company IMV to explore a preclinical research collaboration that could combine each company's immunotherapy technologies.
Special Feature
IMV: Imaging boosts precision in radiation therapy

Radiation therapy is a relatively stable market, with procedure volume growing at an average annual rate of 2%. But major technological changes in radiation oncology are brewing under the surface, according to a new report by IMV Medical Information Division. Read more